PATENT CLAIM ANALYSIS

Application Number: 15914197
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "006500"]

Abstract:
The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.

Claim (Index 1):
A method of improving glycemic control in a patient with type 2 diabetes mellitus inadequately controlled by treatment with metformin, the method comprising administering to the patient in need thereof a pharmaceutical composition comprising:\n (a) lixisenatide or a pharmaceutically acceptable salt thereof at a concentration of 33 \u03bcg/mL, and (b) insulin glargine or a pharmaceutically acceptable salt thereof at a concentration of 100 U/mL; wherein the glycemic control of the patient with type 2 diabetes mellitus inadequately controlled by treatment with metformin is improved.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.7
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14965586', '14781857', '15646760', '13467707', '13467757']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6758494289477629
- 35 USC 102 Novelty (BERT): 0.7291118268456106
- Combined Prediction Score: 0.6811756687375478
- Mean Citation Score: 591.989484
- Max Citation Score: 821.1425
- Similarity Product: 791.6929022006692

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test